The 6 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 1.75, with a high estimate of 10.00 and a low estimate of 1.00. The median estimate represents a +311.18% increase from the last price of 0.43.
The current consensus among 8 polled investment analysts is to Hold stock in Outlook Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.06
Reporting Date Dec 21
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.